Loading organizations...
§ Private Profile · 430 East 29th Street, New York, NY 10016, United States of America
Software platform for low-pass whole genome sequencing & high-throughput genomics analysis for research, diagnostics, personalized medicine.
Based in New York City, New York, Gencove provides a hardware-agnostic software platform for low-pass whole genome sequencing that enables high-throughput genomics analysis across human, plant, and animal species. The company operates a software-as-a-service business model that replaces traditional genotyping arrays with broader variant discovery, offering assay development, advanced data analytics, and API access for external developers. Operating with a team of approximately 25 employees, the business generates under $5 million in annual revenue through its enterprise services and direct-to-consumer genetic testing kits. Its sequencing and analytics solutions support research, diagnostics, and personalized medicine initiatives for major institutional customers, including Stanford, Oxford, GSK, and Boehringer Ingelheim. The organization was established by a team of scientists and engineers with expertise in population genetics and bioinformatics, and is currently led by Chief Executive Officer Geoff Benton.
Gencove has raised $16.0M across 3 funding rounds.
Gencove has raised $16.0M in total across 3 funding rounds.
Gencove has raised $16.0M across 3 funding rounds. Most recently, it raised $10.0M Series A in October 2021.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Oct 1, 2021 | $10M Series A | Lewis & Clark Agrifood | Spero Ventures, Balaji Srinivasan, Techammer, Third Kind Venture Capital, Version ONE Ventures | Announced |
| Mar 13, 2019 | $3M Venture Round | Shripriya Mahesh | Alexandria Venture Investments, Burst Capital, Third Kind Venture Capital, Version ONE Ventures | Announced |
| Mar 1, 2019 | $3M Seed | Spero Ventures | Balaji Srinivasan, Alexandria Venture Investments, Burst Capital, Third Kind Venture Capital, Version ONE Ventures | Announced |
Gencove is a genomics technology company that provides a hardware-agnostic, high-throughput, cost-effective software-as-a-service platform for whole genome sequencing, delivering genome-wide information at the price of genotyping arrays.[1][2] It serves academic institutions, clinical laboratories, agriculture, pharma, and researchers in human, plant, and animal genomics by solving the problem of expensive, low-resolution genetic analysis through low-pass whole genome sequencing (low-pass WGS), which uncovers more variants at lower costs than traditional arrays.[2][3] The platform includes end-to-end tools like Explorer analysis cloud for data organization, visualization, and querying, enabling faster insights without managing complex infrastructure.[2][4] Gencove's growth is fueled by skyrocketing demand for large-scale genomics, with applications in disease risk prediction, breeding, and population studies, while optimizing compute costs via technologies like AWS Graviton for more science per budget.[1][5]
Gencove emerged from a team of biologists, geneticists, data scientists, engineers, and business leaders motivated to advance global health and sustainability through software-based genomic technology.[1] Key figures include Geoff Benton, Ph.D., Chase Mazur, Tatiana Rodriguez, Mislav Cimpersak, Lex Flagel, Ph.D., Miguel Liezun, Forest Dussault, and Gillian Belbin, who developed low-pass WGS to replace costly genotyping arrays and enable discovery of new variants beyond the <0.1% genome coverage of arrays.[1][3] The idea gained traction by opening the platform via API—like "Stripe for genomics"—allowing researchers to launch studies in one day, handle logistics, and import data from competitors like 23andMe or AncestryDNA.[3] Early pivotal moments include partnering with automation like Formulatrix for reproducible sequencing and porting workloads to cost-efficient compute, accelerating discoveries in personalized medicine and beyond.[3][5]
Gencove stands out in genomics through these key advantages:
Gencove rides the wave of plummeting sequencing costs and exploding demand for large-scale genomics, driven by biobanks, population studies, and precision applications in health, agriculture, and pharma.[1][5][6] Timing is ideal as hardware advances enable population-scale data, but analysis bottlenecks persist—Gencove abstracts complexity with cloud tools, supercharging under-resourced teams amid AI-bio convergence.[2][4] Market forces like budget constraints and carbon-aware compute favor its optimizations, while influences include democratizing WGS for rare variant discovery, GWAS, disease risk, and trait tracking, bridging DTC genomics gaps and fostering ubiquitous genetic utilization.[3][6][7]
Gencove is poised to expand its Explorer cloud and API ecosystem, integrating more long-read sequencing and AI-driven analytics to handle ever-larger biobanks and real-time predictions.[2][4][5] Trends like sustainable compute, personalized medicine, and agribiotech (e.g., climate-resilient crops via genomics) will propel growth, potentially capturing share from array giants as WGS becomes standard.[3][6] Its influence may evolve into a genomics infrastructure layer, empowering startups and enterprises to innovate faster—unlocking healthier, more sustainable outcomes from genetic data at scale, much like its core mission to get more science done.[1][5]
Gencove has raised $16.0M in total across 3 funding rounds.
Gencove's investors include Lewis & Clark AgriFood, Spero Ventures, Balaji Srinivasan, Techammer, Third Kind Venture Capital, Version One Ventures, Shripriya Mahesh, Alexandria Venture Investments, Burst Capital.